Autolus Therapeutics (FRA:6A3A) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 01, 2026)


FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
68 GF Score
Price €1.42
GF Value €17.24
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Autolus Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:6A3A vs FBRX, SGMT, EDIT: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Autolus Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


FRA:6A3A
68GF Score
Autolus Therapeutics PLC FRA:6A3A
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.42 is trading 91.8% below its estimated GF Value™ of €17.24. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €17.24 vs. price of €1.42 (91.8% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for FRA:6A3A

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.42
Price
€17.24
GF Value